PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE
Clinical trials for PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE explained in plain language.
Never miss a new study
Get alerted when new PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE trials appear
Sign up with your email to follow new studies for PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New inhaled drug aims to help patients with lung scarring and high blood pressure
Disease control TerminatedThis phase 3 trial tests an inhaled drug called seralutinib for people with pulmonary hypertension (high blood pressure in the lungs) caused by interstitial lung disease (lung scarring). About 480 adults will receive either seralutinib or a placebo for 24 weeks, followed by a lon…
Matched conditions: PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE
Phase: PHASE3 • Sponsor: GB002, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New inhaled drug aims to ease lung scarring and heart strain
Disease control OngoingThis Phase 2 trial tests an inhaled medication called mosliciguat in 135 people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs. Participants are randomly assigned to receive either the drug or a placebo for 16 weeks. The study measure…
Matched conditions: PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE
Phase: PHASE2 • Sponsor: Pulmovant, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC